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Abstract
Antibodies are among the most important tools for protein detection but, prior to their usage,
proper validation of their appropriateness for given applications is required. The utility of an
antibody depends on its sensitivity and specificity. We studied these two aspects in a panel of
commercial antibodies against Shb, a platform protein involved in receptor tyrosine kinase
signalling, but the function of which is still incompletely understood. Several of the antibodies
showed shortcomings or were not acceptable for detection of the endogenous protein. The
few that could detect Shb were doing so in either western blotting or immunoprecipitation
experiments but a given antibody could not work in both applications. This article provides a
resource for the available molecular tools that can be used in future research on Shb.
Introduction
Shb (SH2 domain-containing adapter protein B) is a 55 kDa adapter protein that is expressed
in a wide range of human and mice tissues (http://www.ebi.ac.uk/gxa/genes/ENSG00000107
338) [1]. Shb consists of a proline rich motif at the N-terminal that is followed by a phospho-
tyrosine-binding domain (PTB) and a C-terminal SH2 domain [2]. It can form molecular
complexes with its binding partners and modulate various physiological functions including
apoptosis, differentiation, proliferation and cytoskeletal alterations [3]. The in vivo role of Shb
was evaluated by investigating global knock-out (KO) animals. In the C57/BL6 background,
absence of Shb is lethal whereas it is viable in mixed 129Sv/C57Bl6/FVB and in BALB/c back-
grounds [4]. However, even in the viable strains, the absence of Shb results in severe abnormal-
ities affecting the vasculature, haematopoiesis, reproduction and glucose homeostasis. This
indicates that Shb plays key roles during normal development and for homeostasis [3]. At the
molecular level, it is poorly understood how Shb mediates these important physiological func-
tions. Therefore, development of tools that allow Shb detection in various experimental con-
ditions is of primary importance. In this study therefore, we have evaluated the specificity of
seven commercially available and one custom-made anti-Shb antibodies in recognizing endog-
enously expressed Shb in accordance with the Western Blotting Minimal Reporting Standards
(WBMRS) [5]. Our results show that most of these antibodies are unsuited to detect endoge-
nous levels of the Shb protein and that great caution should be used to interpret the data
derived from experiments employing these antibodies.
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Materials and methods
Cell culture
HEK 293T cells were obtained from the American Type Culture Collection (ATCC) (reference
CRL-3216). HEK 293T and CE12 cell lines were kept in DMEM (Invitrogen, catalogue no.
61965) supplemented with 10% fetal bovine serum (Gibco, catalogue no. 10499–044). They
were grown at 37˚C in a 5% CO2 atmosphere and kept at a confluency ranging from 10% (i.e.
after splitting) to 80% (i.e. before splitting).
Generation of CE12 cell line
The HEK 293T-derived CE12 cell line has one of its Shb alleles tagged with the V5 sequence
(at the carboxy-terminal end of the protein). The V5 tag was introduced by genome editing
using a double nicking CRISPR/Cas9 strategy that minimizes off-target insertions [6]. This
approach requires the expression of a Cas9 nickase mutant and a pair of single guide RNAs
(sgRNA) in order to introduce targeted single stranded breaks (SSBs) in opposite strands of
the genomic DNA [6]. An exogenous single stranded DNA–the ultramer–was provided as a
V5-encoding DNA donor to be inserted in the Shb alleles during homology-directed repair of
the SSBs. The ultramer contains, at its extremities, two arms of perfect homology to the 6th
(last) exon of Shb. The central region of the ultramer bears the V5 sequence [7]. The single
guide RNAs and the ultramer were designed using the CRISPR Design web tool (http://crispr.
mit.edu/) (Table 1).
To produce a given sgRNA, two DNA oligonucleotides with complementary sequences
were synthetized (Microsynth, Balgach, Switzerland), annealed and subcloned into specific
Cas9-encoding vectors. For sgRNA1, the subcloning was performed in pSpCas9n(BB)-2A-
Puro (PX462) (Addgene plasmid no. 62987) and for sgRNA2 in pSpCas9n(BB)-2A-GFP
(PX461) (Addgene plasmid no. 48140). The cells were then transfected with 2 μg of each plas-
mid and 1 micromole of the ultramer (chemically synthetized by Integrated DNA Technolo-
gies, Coralville, IA) using calcium phosphate-based transfection [8]. Forty-eight hours post-
transfection, transiently transfected cells were selected in the presence of puromycin (Thermo,
Whaltam, MA) (2000 ng/ml for 200,000 cells in 2 ml) for 24 hours. At the end of the antibiotic
selection, single cell clones were generated by limiting dilution and the integration of the V5
tag was assessed by massive parallel sequencing using an Illumina MiSeq sequencer. Briefly, a
region within the 6th exon of Shb was amplified by PCR using oligonucleotide #1385 TCGTCG
GCAGCGTCAGATGTGTATAAGAGACAGACCAAAGAGAAA TACGTTCTG (underlined se-
quence: region annealing with residues 1952–1972 of Shb mRNA, NM_003028.2) and oligonu-
cleotide #1386 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGCATACACACAACACAAAC
Table 1. Sequences used to knock-in the V5 epitope in the Shb gene.
Orientation Sequence
sgRNA1 3’!5’ CCCTGTGAGCGGACCAGACCTGC
sgRNA2 5’!3’ CTGAGACTTGGAGGTGCCAGAGG
Ultramer CTACCCATCAAAGGGGCTGAGCACTTGTCCCTCCTCTATCCCGTGGCTG
TGAGGACCCTGGGAAAACCAATACCAAATCCACTACTAGGCCTAGACAG
TACATGAGCGGACCAGACCTGCCCTGCTCTGTGACAGAGCCTGAGACTT
GGAGGTGCCAGAGACCCC
Pam sequences (terminal sequences required for Cas9 recognition) are denoted in italics. The underlined sequence encodes for the V5 tag. The ultramer
homology arms match positions 2036–2095 and 2096–2158 of human Shb mRNA (NM_003028.2 NCBI entry). The bold sequence corresponds to a
mutated AGG PAM sequence. This mutation ensures that the ultramer, once knocked in the Shb locus, cannot be targeted by the single guide RNAs.
https://doi.org/10.1371/journal.pone.0188311.t001
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GAC (underlined sequence: region annealing with residues 2212–2192 of Shb mRNA, NM_
003028.2). The non-underlined sequences were used for bar-coding.
Generation of the ShbKO cell line
The Shb knock-out cell line was derived from CE12 cells. Cas9 nickase was used as described
above to generate proximal SSBs, but in this case no ultramer was added. In the absence of an
exogenous donor DNA, non-homologous DNA repair leads to the stochastic appearance of
insertions and deletions around the SSBs. The sgRNAs used were CCGAGGCGAGCGGCCTTC
GCAGC and TCCGCCGCCTCGGCGTCCTGCGG (PAM sequences underlined), located in the
1st exon of Shb and corresponding to positions 664–686 and 713–735 of human Shb mRNA,
NM_003028.2). Cells expressing both plasmids were selected and clones were isolated as
described above. The presence of insertions or deletions in the different alleles of Shb was
assessed by massive parallel sequencing. The amplified region was located in the 1st Shb exon
and the oligonucleotides used were TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG CTTCA
GCTTGGGCAACAG (underlined sequence: region annealing with residues 592–609 of Shb
mRNA, NM_003028.2) and GTCTCGTGGGCTCGG AGATGTGTATAAGAGACAG TCGAAGTC
TCGCTCCTTCTG (underlined sequence: region annealing with residues 846–827 of Shb
mRNA, NM_003028.2).
RNAi
CE12 cells were plated at a density of 2 x 105 in 6-well dishes. The next day, the cells were
transfected with 40 pmoles of an siRNA targeting Shb (GCACAUGAAACUGGCCAAA, Micro-
synth) or a control siRNA (AllStars Negative Control siRNA, catalogue no. 1027280; Qiagen,
Hilden, DE) using 2 μl of Lipofectamine RNAiMAX (Invitrogen, catalogue no. 13778150)
diluted in 200 μl of Opti-MEM (Gibco, catalogue no. 31985062). These siRNA sequences were
derived using bioinformatics and research computing online tools from the Whitehead insti-
tute (http://sirna.wi.mit.edu). The following day, the culture medium was changed and the
cells were subjected to an additional round of transfection. Forty-eight hours after the last
transfection, cells were lysed in NP-40 lysis buffer.
Cell transfection
HEK 293T were plated at a density of 2 x 105 in 6-well plates. One day later, they were trans-
fected with 2 μg of either the Stag-Shb-V5.dn3 plasmid (#927) encoding a Shb version tagged
at the N-terminus with the Stag epitope and at the C-terminus with the V5 tag or with the
corresponding empty vector (pcDNA3, #1) using a calcium phosphate-based transfection
method. Twenty-four hours after the transfection, cells were lysed in NP-40 lysis buffer.
Western blotting
After being washed two times with ice cold PBS (0.68% NaCl, 0.04% KH2PO4, 0.15%
NaH2PO4, pH 7.2), cells were lysed in 1 ml of cold NP-40 lysis buffer (Tris-Cl 50 mM pH 8.0,
150 mM NaCl, 1.0% NP-40). Protein quantification was performed by the Bradford technique.
50 μg of protein for each condition was migrated on a 10% polyacrylamide gel and transferred
onto a Trans-Blot nitrocellulose membrane (Bio-Rad catalogue no. 10484060) during 1 hour
at 100 Volts. Membranes were blocked in 5% non-fat milk for one hour at room temperature.
Primary antibodies were diluted according to the manufacturer’s specifications in 5% non-fat
milk in TBS (18 mM HCl, 130 mM NaCl, 20 mM Tris pH 7.2)/0.1% Tween 20 (Table 2). Blots
were incubated over-night at 4˚C with primary antibodies with gentle agitation. Then, blots
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were washed with TBS/0.1% Tween 20 for 20 minutes each (x4) and incubated with secondary
antibodies for 1 hour at room temperature. Blots were visualized with the Odyssey infrared
imaging system (LICOR Biosciences, Bad Homburg, Germany).
Immunoprecipitation
Cells were washed with PBS and scraped from Petri dishes in ice-cold PBS, centrifuged and
gently resuspended in NP-40 lysis buffer. After 15 minutes of incubation at 4˚C with rotation,
cellular debris was cleared from the whole cell extracts by centrifugation (13,000 g, 5 minutes).
Shb was immunoprecipitated from whole cell lysates by overnight incubation at 4˚C with the
corresponding antibodies, followed by incubation for 1 hour at 4˚C with 20 μl of protein-G
coupled magnetic Dynabeads (ThermoFisher, Waltham, MA). The immunoprecipitates were
then washed 3 times for 15 minutes with fresh ice-cold NP-40 lysis buffer. Additional aliquots
of the whole cell lysates plus the immunoprecipitates were then subjected to SDS-PAGE and
western blotting as described in the previous section.
Subcellular fractionation
Cells were treated with siRNA, as described in the previous section. Cells were then washed
once with ice-cold PBS. 440 μL of buffer A (HEPES 10 mM pH 7.9, KCl 10 mM, EDTA 0.1
mM, EGTA 0.1 mM, DTT 1 mM) were added to the cells, which were scraped and transferred
to a 1.5 mL tube and kept in ice for 15 minutes. Afterwards, 60 μL of buffer A (containing 5%
NP-40 solution) was added to each tube, which was further incubated for 5 minutes on ice.
These tubes were briefly vortexed, then nuclei were pelleted by centrifugation (800 g, 5 min-
utes) and the supernatant (cytoplasmic fraction) was transferred to a new tube. The pelleted
nuclei were further washed several times in buffer A to remove contaminating cytoplasmic
proteins, while the cytoplasmic fraction was centrifuged again to pellet contaminating nuclei.
The nuclei were then lysed by resuspending the pellet in 50 μL buffer B (HEPES 20 mM pH
7.9, NaCl 400 mM, EDTA 1 mM, EGTA 1 mM, DTT 1 mM) and subjected to 4 cycles of vor-
texing plus a 5 minute-long incubation on ice. Afterwards, unbroken nuclei were pelleted by
centrifugation (13,000 g, 5 minutes) and the supernatant (nuclear fraction) was transferred to
a new tube.
Results and discussion
We purchased a series of antibodies from various suppliers that were sold as Shb-specific
(Table 2). Antibodies targeting conformational epitopes are usually preferred for applications
requiring that proteins are kept in their native state such as immunoprecipitation and flow
cytometry. In contrast, antibodies targeting linear epitopes are in principle better suited for
applications where the proteins are denatured including western blotting, immunocytochem-
istry and immunohistochemistry. Since the purchased antibodies are falling in these two cate-
gories (Table 2), we tested them both by Western blotting and for immunoprecipitation. The
HEK 293T cell line was chosen for these analyses because they express Shb at the mRNA and
protein levels (ProteomeScout Probeset ID: 204656_at) [9]. Two positive controls were used.
The first one corresponds to an over-expression system resulting from HEK 293T cells tran-
siently transfected with a cytomegalovirus (CMV) promoter-driven Stag-Shb-V5 construct.
The second one corresponds to an endogenous expression situation where the HEK 293T-
derived CE12 cell line has one of its Shb alleles V5-tagged (see the methods). As a negative con-
trol, Shb was knocked-down in the CE12 cell line using Shb-specific siRNAs. A shown in Fig
1, a V5-specific antibody efficiently detected over-expressed Shb-V5. Endogenously expressed
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Shb-V5 was also clearly detected in the CE12 cells. The corresponding band disappeared in the
Shb-silenced CE12 cells, demonstrating the specificity of our cellular system.
The Shb antibodies were first tested by Western blotting and the results are reported in
Fig 2.
Abcam 129190. This antibody recognizes a strong band migrating at around 55 kDa, the
expected size of Shb in empty vector-transfected HEK 293T cells. This band, however, neither
augmented in Shb-overexpressing cells nor diminished in Shb-silenced cells. Hence, Abcam
129190 is specific for a Shb-unrelated 55 kDa migrating protein.
Abcam 94851. This antibody was unable to light up distinct bands on western blots, even
though manufacturer’s recommendations were followed. This antibody may have some affin-
ity for the Shb protein but was not shown here. Alternatively, this antibody might not recog-
nize the protein at all.
Abcam 175553, Abcam 98007, custom-made Genscript, Sigma 2104743. These four
antibodies only detected overexpressed Shb but not endogenous Shb. They are therefore
able to recognize Shb but not with much potency (Abcam 98007 was the weakest of all) and
Table 2. Antibodies tested in this study.
Name and Catalogue no. Immunogen Antibody type Lot number Supplier Concentration/
Dilution
1 Anti-Shb/Shf (C-20): sc-530 C-terminus (last 50 amino acids) of human Shb Rabbit
Polyclonal
F2013 Santa Cruz
Biotechnology
2 μg/ml
2 Anti-Shb/Shf (B-1): sc-
74483
C-terminal amino acids (380-509) of human Shb Mouse
monoclonal
K0207 Santa Cruz
Biotechnology
2 μg/ml
3 Anti-Shb: SAB1300181 Center amino acids (240-275) of human Shb Rabbit
polyclonal
020M0467 Sigma-Aldrich 1 μg/ml
4 Anti-Shb: SAB2104743 N-terminal amino acids (1-51) of human Shb Rabbit
polyclonal
QC27580 Sigma-Aldrich 1 μg/ml
5 Anti-Shb: ab94851 N-terminal amino acids (36-85) of human Shb Rabbit
polyclonal
GR65245-1 Abcam 1 μg/ml
6 Anti-Shb: ab175553 C-terminal amino acids (67-95) of mouse Shb
conjugated to keyhole limpet haemocynin (KLH)
Rabbit
polyclonal
GR259990-
1
Abcam 1/1000
7 Anti-Shb (EPR7976):
ab129190
C-terminus of human Shb (amino acids 481-494) Rabbit
monoclonal
GR93075-1 Abcam 1/1000
8 Anti-Shb: ab98007 N-terminal amino acids (1-50) of human Shb Rabbit
polyclonal
GR54367-3 Abcam 1 μg/ml
9 Anti-Shb The whole recombinant human Shb protein Rabbit
polyclonal
Custom
made
Genscript 1 μg/ml
10 Anti-V5: A190-120A Amino acids (95-108) of RNA polymerase alpha
subunit of simian virus 5 conjugated to KLH
Rabbit
polyclonal
7 Bethyl 1 μg/ml
11 Anti-V5: 46–1157 Mouse
monoclonal
1231236 Thermo-Fisher
scientific
1.18 μg/ml
12 Anti-α-tubulin: MCA77G Rat
monoclonal
BioRad Serotec 1/5000
13 Anti-PARP: 9542 Rabbit
polyclonal
14 Cell Signaling 1/1000
14 Anti-β-actin: 4970 Rabbit
monoclonal
14 Cell Signaling 1/5000
15 Anti-Rabbit antibody Alexa
Fluor 680: A-21076
Goat
polyclonal
1584296 Thermo-Fisher
Scientific
200 ng/ml
16 Anti-Mouse antibody
DyLight 800: SA5-10176
Goat
polyclonal
RF2212068 Thermo-Fisher
Scientific
200 ng/mL
The table lists the antibodies used in the present work, their properties, the providers and how they were employed in Western blotting.
https://doi.org/10.1371/journal.pone.0188311.t002
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consequently cannot be used to study the natural expression of the protein. If only ectopic Shb
is to be monitored, Abcam 175553 and Sigma 2104743 can be recommended for their low
background detection.
Sigma 1300181. This antibody lit up many bands in HEK 293T cells. One of them corre-
sponding to Shb (indicated by an arrow on the blot) because it disappeared in the Shb-silenced
cells. This antibody is nevertheless of little use for Shb research because of the extent of non-
specific detection, including bands that migrate very close to the protein of interest.
Santa Cruz 530. This antibody behaved like Sigma 1300181 but it lit up fewer non-specific
bands. Unfortunately, a strong non-specific band was detected very close to Shb, diminishing
the usefulness of this antibody for investigating the endogenous protein. It might be potentially
a useful antibody to monitor Shb when it is over-expressed though.
Santa Cruz 74483. This antibody proved to be the most specific one. It was clearly able to
detect the endogenous Shb protein. The strongest signal corresponded to Shb and only one or
two non-specific weaker bands were detected.
To further validate the specificity of these last two antibodies, we performed western blotting
using them together with an anti-V5 antibody produced in a different host. The Santa Cruz 530
antibody detected one band which coincided with the band detected by the V5 antibody (Fig
3A), although the non-specific band found closest to Shb obscures its detection. The Santa Cruz
74483 antibody detected a more intense band, which also coincided with the band detected by
the V5 antibody (Fig 3B). Although a non-specific band was detected in its proximity, it was
much weaker than the Shb band, making it the antibody of choice for western blot application.
We next tested the performance of the antibodies during immunoprecipitation of cell
lysates prepared from HEK 293T, the CE12 clone (which expresses endogenous V5-tagged ver-
sions of Shb), and Shb knock-out cells (Fig 4A). The presence of Shb in the immunoprecipi-
tates was assessed by Western blotting using the Santa Cruz 74483 and the anti-V5 antibodies.
Fig 4B and Fig 5 report the results of these experiments.
Three antibodies (Sigma 2104743, Abcam 175553 and Abcam 98007) were able to immu-
noprecipitate Shb, identified as a band detected by both the Santa Cruz 74483 and anti-V5
antibodies but absent from the Shb knock-out samples (Fig 4B). The other two antibodies
tested, Sigma 1300181 and Abcam 94851, were very poor at immunoprecipitating Shb.
Fig 1. V5-tagged Shb is specifically detected with an anti-V5 antibody. The V5 signal corresponding to
Shb-V5 was detected by western blot. HEK 293T cells were transfected with empty plasmid or a Stag-Shb-V5
encoding plasmid. To test the specificity of the signals, the CE12 cell line bearing an endogenous V5-tagged
Shb allele was knocked-down for Shb (siRNAShb) or treated with control siRNA (siRNASCR). Arrowheads point
to Shb-V5. Equal amounts of proteins were loaded (50 μg) on each lane.
https://doi.org/10.1371/journal.pone.0188311.g001
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Because of their absence of specificity, Abcam 129190 and custom-made Genscript were not
tested (see Fig 2).
The ability to recognize endogenous Shb in immunoprecipitation but not during Western
blotting suggests that Sigma 2104743, Abcam 175553 and Abcam 98007 may recognize a
conformational epitope. Of note, these three antibodies, while not able to reveal endogenous
Shb on Western blots, detected over-expressed Shb on membranes. It is possible therefore
that a small fraction of over-expressed Shb on Western blot membranes displays the native
Fig 2. Assessment of nine anti-Shb antibodies. Anti-Shb antibodies were tested by western blotting for their ability to recognize their antigen in
HEK 293T cells transfected with either empty plasmid or a Stag-Shb-V5 plasmid, or in CE12 cells, treated with control or Shb-specific siRNA. Whole
cell lysates are those that were used in Fig 1. Arrowheads point to Shb-V5; *, unspecific signals.
https://doi.org/10.1371/journal.pone.0188311.g002
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conformation of the epitopes recognized by these antibodies. Neither 74483 nor 530 from
Santa Cruz were able to precipitate Shb in comparable conditions (Fig 5), suggesting that the
epitope recognized by these antibodies is indeed only revealed when the protein is denatured.
Finally, we decided to use the most specific antibody (Santa Cruz 74483) to determine
whether Shb was located in the cytoplasm or in the nucleus. We performed cell fractionation
on cells treated with control or Shb-specific siRNAs. Fig 6 shows that the cytoplasmic fraction
was devoid of the PARP nuclear marker. The α-tubulin cytoplasmic marker was detected in
the nuclear fraction but not as intensely as in the cytoplasmic fraction, suggesting some cyto-
plasmic contaminants in the nuclear fraction. However, α-tubulin can translocate in the
nucleus in some situations [10] and consequently one may underestimate the purity of the
nuclear fraction using the α-tubulin marker. In contrast to α-tubulin, Shb was detected with
similar intensities in both cytoplasmic and nuclear fractions, suggesting that its presence in
the nuclear fraction is not due to a cytoplasmic contamination. Shb has been previously de-
scribed as a scaffolding protein which regulates tyrosine-kinase signalling through its inter-
actions with PDGFR, FGFR, Fak or Src among others [3]. Its presence in the cytoplasm is
therefore expected and confirms an earlier observation [11] regarding its location, which
was assessed using immunocytochemistry. The nuclear location of Shb was not anticipated,
because canonical nuclear location signals are not found in the Shb sequence. Interestingly,
Shb associates with the tyrosine kinase Frk, which has a nuclear location signal and is found in
the nucleus [2]. Further studies will be needed to establish how Shb enters the nucleus and the
physiological relevance of this translocation.
Fig 3. Endogenous Shb-V5 can be detected simultaneously by an anti-V5 antibody and a Shb
antibody. CE12 cells, which have one of their Shb allele tagged with V5, were treated with control or Shb-
directed siRNAs. Western blots of the cell extracts were performed using simultaneously a Shb-specific
antibody (panel A: Santa Cruz 530; panel B: Santa Cruz 74483) and an anti-V5 antibody. The Santa Cruz 530
antibody detected the same band as the anti-V5 antibody (arrowhead) but also many non-specific bands
(filled stars), including an intense one in the proximity of the Shb band itself (open star). The Santa Cruz
74483 antibody detected the same band as the anti-V5 antibody (arrowhead) with much more affinity than the
closest non-specific band (open star).
https://doi.org/10.1371/journal.pone.0188311.g003
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Fig 4. Antibodies that fail to detect Shb in western blot can be used to immunoprecipitate it. Whole cell extracts were prepared from HEK 293T
cells encoding endogenous wild-type Shb (WT), HEK 293T CE12 cells having one of their alleles tagged with V5 (V5-tag) or HEK 293T cells knock-out for
Shb (KO). A: The lysates (40 μg of total protein) were incubated with antibodies against Shb (left panel) or V5-tag (right panel). Arrowheads indicate the
band corresponding to Shb. In each case, β-actin was used as a loading control. B: Shb was immunoprecipitated from the same whole cell extracts (1.5
mg of total protein) using the six indicated rabbit antibodies. The immunoprecipitates were analysed by western blot using a mouse antibody against Shb
(upper panel) and then were reblotted with a rabbit antibody against V5-tag (lower panel). Arrowheads indicate the band corresponding to Shb. The insets
show a higher exposure of the areas indicated by the black corners in the upper panel. * indicates the location of the antibody heavy chains, against which
the goat secondary antibodies react weakly (in the case of the anti-mouse secondary) or more strongly (in the case of the anti-rabbit secondary). Pre-
immune IgG was loaded to allow for the unequivocal identification of the heavy chain.
https://doi.org/10.1371/journal.pone.0188311.g004
Validation of Shb antibodies
PLOS ONE | https://doi.org/10.1371/journal.pone.0188311 December 1, 2017 9 / 12
Fig 5. Antibodies that detect SHB in western blot fail to immunoprecipitate it. HEK 293T CE12 cells
having one of their alleles tagged with V5 (V5-tag) or HEK 293T cells knock-out for Shb (KO) were used to
prepare whole cell extracts, which were then used as material for the immunoprecipitations (40 μg of total
protein). Shb was immunoprecipitated from the cell extracts (2 mg of total protein) using the 74483 and 530
antibodies from Santa Cruz. An anti-V5 mouse antibody was used for control immunoprecipitations. The
samples were then analysed by western blot using a rabbit anti-V5 antibody. The arrowhead indicates the
band corresponding to Shb. The bottom panel shows a lower exposure of the indicated area to better
distinguish the heavy chain of the antibody used in the immunoprecipitation (indicated by *), against which the
goat anti-rabbit secondary antibodies react (weakly in the case of mouse primary antibodies).
https://doi.org/10.1371/journal.pone.0188311.g005
Fig 6. Shb is located in the cytoplasm and in the nucleus. HEK 293T cells, treated with either control or
Shb siRNA, were used to isolate nuclear and cytoplasmic cell fractions. These were analysed by western blot
using a cytoplasmic marker (α-tubulin), a nuclear marker (PARP) and Shb.
https://doi.org/10.1371/journal.pone.0188311.g006
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Antibody validation is an essential step prior to their utilisation, and this becomes especially
relevant when the literature describing prior usage is scarce. Here we show that antibodies sold
on the market as Shb-specific can be very specific for a protein distinct for Shb (e.g. Abcam
129190), can detect virtually nothing (e.g. Abcam 94851) or can be highly non-specific (e.g.
Sigma 1300181). Some were able to recognize Shb but only in certain applications. For exam-
ple, Santa Cruz 74483 was quite effective at detecting endogenous Shb on Western blot mem-
branes but could not pull-down the protein from cells lysates. Conversely, Sigma 2104743,
Abcam 175553 and Abcam 98007 were able to immune-precipitate Shb but could not detect
the endogenous protein on membranes.
It is not uncommon for researchers to be confronted with poor results when using com-
mercial antibodies [12–14]. Inadequate antibody validation has led whole research projects to
go to waste leading to paper retractions [15] and resources unduly spent. Recent surveys indi-
cate that still too many researchers do not realize the negative impacts that poor antibody vali-
dation may have on their research [16]. It is therefore critical to perform thorough validation
of antibodies before they are used. The approach employed in this article to test anti-Shb anti-
bodies closely matches the initial part of the Rimm Lab Algorithm for antibody validation
[17]. Other approaches can be used such as those relying on proteomic analyses of the bound
ligands to validate antibodies for immunoprecipitation purposes for example [18]. Such inves-
tigations provide essential resources for specific communities of researchers, who can refer to
these results instead of themselves duplicating time- and resource-consuming validation pro-
cesses. Growing concern about the specificity of commercial antibodies have also prompted
the creation of open resources available online [19]. While these not always follow strict crite-
ria for antibody validation, users can still amend or complement the information provided by
the retailer of a given antibody for different applications. While this crowdsourced approach
to antibody validation may be less rigorous compared to results published in scientific jour-
nals, it can provide some retailer-independent antibody validation.
In conclusion, the increasing availability of commercial antibodies makes antibody quality
a growing concern. Antibody validation, done by researchers or provided by open access
resources, will have to become the norm if results aspire to be trustworthy and reproducible.
The data shown here contribute to this effort by reporting information on the quality of com-
mercially available Shb-specific antibodies. This should help researchers planning adequate
experiments to study the biological properties of this relatively poorly known protein.
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